Company intelligence / Profile preview
i-Cordis
Baltimore, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
i-Cordis is developing pegydone, a PEGylated derivative of pirfenidone, as an immunomodulatory oral small molecule for heart failure with preserved ejection fraction (HFpEF); supported by completed rodent proof‑of‑concept studies and a Phase II NHLBI SBIR grant to complete critical preclinical de‑risking prior to IND filing.[1][2][4][6]
- Therapeutic areas
- CardiovascularPulmonologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johns Hopkins University (laboratory of Dr. Luigi Adamo for preclinical cardiac immunology and HFpEF models)[1][6]Washington University in St. Louis (foundational IP on pegydone / PEGylated pirfenidone; patent application filed by WashU in 2018)[2]
Beyond the preview
Go deeper on i-Cordis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on i-Cordis.